TY - JOUR
T1 - Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels
AU - Webster, RG
AU - Brain, Keith
AU - Wilson, RH
AU - Grem, JL
AU - Vincent, A
PY - 2005/12/1
Y1 - 2005/12/1
N2 - 1 Oxaliplatin, an effective cytotoxic treatment in combination with 5-fluorouracil for colorectal cancer, is associated with sensory, motor and autonomic neurotoxicity. Motor symptoms include hyperexcitability while autonomic effects include urinary retention, but the cause of these side-effects is unknown. We examined the effects on motor nerve function in the mouse hemidiaphragni and on the autonomic system in the vas deferens.
2 In the mouse diaphragm, oxaliplatin (0.5 mM) induced multiple endplate potentials (EPPs) following a single stimulus, and was associated with an increase in spontaneous miniature EPP frequency. In the vas deferens, spontaneous excitatory junction potential frequency was increased after 30 min exposure to oxaliplatin; no changes in resting Ca2+ concentration in nerve terminal varicosities were observed, and recovery after stimuli trains was unaffected.
3 In both tissues, an oxaliplatin-induced increase in spontaneous activity was prevented by the voltage-gated Na+ channel blocker tetrodotoxin (TTX). Carbamazepine (0.3 mm) also prevented multiple EPPs and the increase in spontaneous activity in both tissues. In diaphragm, beta-pompilidotoxin (100 mu M), which slows Na+ channel inactivation, induced multiple EPPs similar to oxaliplatin's effect. By contrast, blockers of K+ channels (4-aminopyridine and apamin) did not replicate oxaliplatin-induced hyperexcitability in the diaphragm.
4 The prevention of hyperexcitability by TTX blockade implies that oxaliplatin acts on nerve conduction rather than by effecting repolarisation. The similarity between beta-pompilidotoxin and oxaliplatin suggests that alteration of voltage-gated Na+ channel kinetics is likely to underlie the acute neurotoxic actions of oxaliplatin.
AB - 1 Oxaliplatin, an effective cytotoxic treatment in combination with 5-fluorouracil for colorectal cancer, is associated with sensory, motor and autonomic neurotoxicity. Motor symptoms include hyperexcitability while autonomic effects include urinary retention, but the cause of these side-effects is unknown. We examined the effects on motor nerve function in the mouse hemidiaphragni and on the autonomic system in the vas deferens.
2 In the mouse diaphragm, oxaliplatin (0.5 mM) induced multiple endplate potentials (EPPs) following a single stimulus, and was associated with an increase in spontaneous miniature EPP frequency. In the vas deferens, spontaneous excitatory junction potential frequency was increased after 30 min exposure to oxaliplatin; no changes in resting Ca2+ concentration in nerve terminal varicosities were observed, and recovery after stimuli trains was unaffected.
3 In both tissues, an oxaliplatin-induced increase in spontaneous activity was prevented by the voltage-gated Na+ channel blocker tetrodotoxin (TTX). Carbamazepine (0.3 mm) also prevented multiple EPPs and the increase in spontaneous activity in both tissues. In diaphragm, beta-pompilidotoxin (100 mu M), which slows Na+ channel inactivation, induced multiple EPPs similar to oxaliplatin's effect. By contrast, blockers of K+ channels (4-aminopyridine and apamin) did not replicate oxaliplatin-induced hyperexcitability in the diaphragm.
4 The prevention of hyperexcitability by TTX blockade implies that oxaliplatin acts on nerve conduction rather than by effecting repolarisation. The similarity between beta-pompilidotoxin and oxaliplatin suggests that alteration of voltage-gated Na+ channel kinetics is likely to underlie the acute neurotoxic actions of oxaliplatin.
KW - hyperexcitability
KW - beta-pompilidotoxin
KW - neurotoxicity
KW - carbamazepine
KW - voltage-activated Na+ channels
KW - oxaliplatin
KW - neuromyotonia
KW - neuromuscular junction
U2 - 10.1038/sj.bjp.0706407
DO - 10.1038/sj.bjp.0706407
M3 - Article
C2 - 16231011
SN - 1476-5381
SN - 1476-5381
SN - 1476-5381
SN - 1476-5381
SN - 1476-5381
SN - 1476-5381
SN - 1476-5381
SN - 1476-5381
SN - 1476-5381
SN - 1476-5381
SN - 1476-5381
SN - 1476-5381
SN - 1476-5381
SN - 1476-5381
SN - 1476-5381
SN - 1476-5381
SN - 1476-5381
SN - 1476-5381
SN - 1476-5381
VL - 146
SP - 1027
EP - 1039
JO - British Journal of Pharmacology
JF - British Journal of Pharmacology
IS - 7
ER -